JP2013540807A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013540807A5 JP2013540807A5 JP2013535564A JP2013535564A JP2013540807A5 JP 2013540807 A5 JP2013540807 A5 JP 2013540807A5 JP 2013535564 A JP2013535564 A JP 2013535564A JP 2013535564 A JP2013535564 A JP 2013535564A JP 2013540807 A5 JP2013540807 A5 JP 2013540807A5
- Authority
- JP
- Japan
- Prior art keywords
- naltrexone
- pharmaceutically acceptable
- formulation
- layer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims 12
- 229960003086 naltrexone Drugs 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 8
- 206010038678 Respiratory depression Diseases 0.000 claims 8
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 8
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 229960005181 morphine Drugs 0.000 claims 4
- 229960002085 oxycodone Drugs 0.000 claims 4
- 239000008188 pellet Substances 0.000 claims 4
- 229920000642 polymer Polymers 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 239000004084 narcotic analgesic agent Substances 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229940124636 opioid drug Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40675210P | 2010-10-26 | 2010-10-26 | |
| US61/406,752 | 2010-10-26 | ||
| PCT/IB2011/054767 WO2012056402A2 (en) | 2010-10-26 | 2011-10-25 | Formulations and methods for attenuating respiratory depression induced by opioid overdose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013540807A JP2013540807A (ja) | 2013-11-07 |
| JP2013540807A5 true JP2013540807A5 (https=) | 2014-10-09 |
Family
ID=45470606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535564A Pending JP2013540807A (ja) | 2010-10-26 | 2011-10-25 | オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20140030343A1 (https=) |
| EP (1) | EP2632442A2 (https=) |
| JP (1) | JP2013540807A (https=) |
| KR (3) | KR20130097211A (https=) |
| CN (1) | CN103189055A (https=) |
| AU (1) | AU2011322147A1 (https=) |
| BR (1) | BR112013009267A2 (https=) |
| CA (1) | CA2814230A1 (https=) |
| IL (1) | IL225966A0 (https=) |
| MX (1) | MX2013003832A (https=) |
| RU (1) | RU2541159C2 (https=) |
| SG (1) | SG189234A1 (https=) |
| WO (1) | WO2012056402A2 (https=) |
| ZA (1) | ZA201302363B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2092936B1 (en) | 2000-02-08 | 2013-03-20 | Euro-Celtique S.A. | Tamper-resistant oral opioid agonist formulations |
| US20110104214A1 (en) | 2004-04-15 | 2011-05-05 | Purdue Pharma L.P. | Once-a-day oxycodone formulations |
| RU2541159C2 (ru) * | 2010-10-26 | 2015-02-10 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов |
| BR112013019431A2 (pt) * | 2011-02-02 | 2020-10-27 | Alpharma Pharmaceuticals, Llc | composição farmacêutica compreendendo agonista opioide e antagonista sequestrado |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| US9861629B1 (en) | 2015-10-07 | 2018-01-09 | Banner Life Sciences Llc | Opioid abuse deterrent dosage forms |
| PT4293009T (pt) | 2015-12-22 | 2025-09-08 | Zogenix International Ltd | Composições de fenfluramina e métodos de preparação das mesmas |
| WO2017112701A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| US10766925B2 (en) * | 2016-04-11 | 2020-09-08 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Opioid receptor modulators |
| US10335405B1 (en) | 2016-05-04 | 2019-07-02 | Patheon Softgels, Inc. | Non-burst releasing pharmaceutical composition |
| AU2017315273B2 (en) | 2016-08-24 | 2021-04-29 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| AU2018390826B2 (en) | 2017-12-20 | 2024-09-12 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) * | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| AU2019384963B2 (en) | 2018-11-19 | 2022-05-26 | Zogenix International Limited | Methods of treating Rett syndrome using fenfluramine |
| WO2021072055A1 (en) * | 2019-10-11 | 2021-04-15 | Board Of Regents, The University Of Texas System | Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression |
| US20230063876A1 (en) * | 2020-03-02 | 2023-03-02 | Unm Rainforest Innovations | Virus-Like Particle Vaccines for Opioid Drugs |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| KR20240101622A (ko) * | 2021-11-02 | 2024-07-02 | 에날레어 테라퓨틱스 인크. | 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법 |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160222A0 (en) * | 2001-08-06 | 2004-07-25 | Euro Celtique Sa | Opioid agonist formulations with releasable and sequestered antagonist |
| WO2005056087A1 (en) * | 2003-12-05 | 2005-06-23 | Cardinal Health 303, Inc. | Patient-controlled analgesia with patient monitoring system |
| US8168447B2 (en) | 2005-10-07 | 2012-05-01 | University Of Florida Research Foundation, Inc. | Multiple component nanoparticles for multiplexed signaling and optical encoding |
| US20080233156A1 (en) * | 2006-10-11 | 2008-09-25 | Alpharma, Inc. | Pharmaceutical compositions |
| EP2197427A2 (en) * | 2007-09-04 | 2010-06-23 | Alpharma, Inc. | A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer |
| CA2709905A1 (en) * | 2007-12-17 | 2009-06-25 | Alfred Liang | Abuse-resistant oxycodone composition |
| US8623418B2 (en) * | 2007-12-17 | 2014-01-07 | Alpharma Pharmaceuticals Llc | Pharmaceutical composition |
| IT1391530B1 (it) | 2008-07-31 | 2012-01-11 | Cyanagen S R L | Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione |
| CN102231991A (zh) | 2008-07-31 | 2011-11-02 | 生物工程大学精神物质实验室 | 应用于生物分析的活性粒子及其制备方法 |
| RU2541159C2 (ru) * | 2010-10-26 | 2015-02-10 | АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов |
-
2011
- 2011-10-25 RU RU2013117274/15A patent/RU2541159C2/ru not_active IP Right Cessation
- 2011-10-25 BR BR112013009267A patent/BR112013009267A2/pt not_active IP Right Cessation
- 2011-10-25 WO PCT/IB2011/054767 patent/WO2012056402A2/en not_active Ceased
- 2011-10-25 US US13/881,758 patent/US20140030343A1/en not_active Abandoned
- 2011-10-25 MX MX2013003832A patent/MX2013003832A/es not_active Application Discontinuation
- 2011-10-25 CN CN201180051633XA patent/CN103189055A/zh active Pending
- 2011-10-25 KR KR1020137010558A patent/KR20130097211A/ko not_active Ceased
- 2011-10-25 AU AU2011322147A patent/AU2011322147A1/en not_active Abandoned
- 2011-10-25 EP EP11807744.5A patent/EP2632442A2/en not_active Withdrawn
- 2011-10-25 KR KR1020167003000A patent/KR20160017668A/ko not_active Ceased
- 2011-10-25 JP JP2013535564A patent/JP2013540807A/ja active Pending
- 2011-10-25 CA CA2814230A patent/CA2814230A1/en not_active Abandoned
- 2011-10-25 KR KR1020177024247A patent/KR20170102571A/ko not_active Ceased
- 2011-10-25 SG SG2013024583A patent/SG189234A1/en unknown
-
2013
- 2013-04-02 ZA ZA2013/02363A patent/ZA201302363B/en unknown
- 2013-04-25 IL IL225966A patent/IL225966A0/en unknown
-
2015
- 2015-10-26 US US14/922,474 patent/US20160045449A1/en not_active Abandoned
-
2017
- 2017-04-27 US US15/498,617 patent/US20170367987A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013540807A5 (https=) | ||
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| JP2009143964A5 (https=) | ||
| JP2013151541A5 (https=) | ||
| RU2013136350A (ru) | Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист | |
| JP2011137020A5 (https=) | ||
| WO2007013975A3 (en) | Composition containing an opioid agonist and a partial opioid agonist, preferably buprenorphine , for controlling abuse of medications | |
| NZ629468A (en) | Tamper resistant immediate release formulations | |
| JP2017537168A5 (https=) | ||
| JP2014504630A5 (https=) | ||
| JP2009525343A5 (https=) | ||
| JP2015044834A5 (https=) | ||
| JP2017128614A5 (https=) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| WO2015120006A1 (en) | Composition and method for aiding sleep | |
| AU2018370000B2 (en) | Treatment of opioid use disorder, opioid withdrawal symptoms, and chronic pain | |
| WO2004091512A3 (en) | Abuse-resistant oral dosage forms and method of use thereof | |
| WO2010020856A3 (en) | Rate modulated delivery of drugs from a composite delivery system | |
| JP2016535773A5 (https=) | ||
| EA032906B1 (ru) | Твердая лекарственная форма с контролируемым высвобождением и способы ее получения и применения | |
| JP2015523407A5 (https=) | ||
| JP2014528431A5 (https=) | ||
| EP2793868A1 (en) | Multiple unit pellet tablet formulation comprising an opioid | |
| JP2011519930A5 (https=) | ||
| JP2013537915A5 (https=) |